Private Trust Co. NA Acquires 63 Shares of Cencora, Inc. $COR

Private Trust Co. NA increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 3.3% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,996 shares of the company’s stock after purchasing an additional 63 shares during the period. Private Trust Co. NA’s holdings in Cencora were worth $599,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Cencora by 8.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after acquiring an additional 787,858 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Cencora by 7.2% during the first quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after acquiring an additional 363,402 shares during the period. Boston Partners boosted its holdings in shares of Cencora by 8.1% during the first quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after acquiring an additional 404,093 shares during the period. Invesco Ltd. boosted its holdings in shares of Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after acquiring an additional 1,364,433 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Cencora by 9.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after acquiring an additional 154,311 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $324.83 on Monday. The firm’s fifty day moving average price is $300.30 and its two-hundred day moving average price is $293.26. The stock has a market cap of $62.98 billion, a PE ratio of 33.42, a PEG ratio of 1.52 and a beta of 0.63. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $325.70. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. The firm had revenue of $80.66 billion for the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.34 earnings per share. On average, equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio is presently 22.63%.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman directly owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the sale, the chief executive officer owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. The trade was a 11.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,025 shares of company stock valued at $14,831,784 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on COR shares. Mizuho boosted their price objective on Cencora from $316.00 to $334.00 and gave the stock an “outperform” rating in a report on Thursday. Weiss Ratings reiterated a “buy (b)” rating on shares of Cencora in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Evercore ISI set a $340.00 price target on shares of Cencora in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group lifted their price target on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $324.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.